Multiple Myeloma in Relapse Not Yet Recruiting Phase 2 Trials for Daratumumab (DB09331)

IndicationStatusPhase
DBCOND0036092 (Multiple Myeloma in Relapse)Not Yet Recruiting2
clinicaltrials.gov IdentifierTitlePurposeDrugs
NCT04176718Daratumumab, Carfilzomib, Pomalidomide, Dexamethasone In MMTreatment